The Western Washington Intravenous Streptokinase Trial randomized 368 patients with acute myocardial infarction to receive either intravenous streptokinase or standard therapy. The ventriculograms and coronary angiograms obtained in 170 patients 10.4±7.4 days after infarction were analyzed to evaluate the effects of thrombolytic therapy on global and regional systolic function. Streptokinase treatment resulted in a higher patency rate of the infarct-related artery (68.5%) than did standard therapy (44.8%) (p = 0.003). Ejection fraction was higher in streptokinase-treated patients (54% vs. 51%, p = 0.056), and the difference was most marked in patients with anterior myocardial infarction (53% vs. 44%, p = 0.03). Regional wall motion was measured by the centerline method and expressed in mean ± SD motion in 52 normal subjects. There was a trend toward better function of the infarct zone in streptokinase-treated patients (SD, -2.48 vs. -2.70, p = 0.24). Additionally, streptokinase-treated patients had significantly better wall motion of noninfarct areas (SD, 0.36 vs. -0.08, p = 0.02). Treatment effects on function of noninfarct regions were most apparent in the subset of patients with multivessel disease. Thus, intravenous streptokinase preserves left ventricular function in patients with acute myocardial infarction. This benefit includes favorable effects on the function of regions remote from the site of infarction. (Circulation 1988; 78:258-266) R ecent data indicate that the early and longterm prognosis of patients with acute myocardial infarction is improved by the early administration of intravenous thrombolytic therapyl-3 Because most early deaths are related to pump failure, the hypothesized mechanism for this effect is preservation of mechanical function. Supporting evidence has been obtained from studies in which ventricular function was measured before and after thrombolytic therapy. Successful reperfusion has usually resulted in an improvement in global or regional function, whereas nonreperfusion has been associated with no improvement or further functional impairment. [4] [5] [6] For several reasons, major differences in global ventricular function have been infrequently observed in randomized trials comparing intracoronary streptokinase (SK) treatment with conventional therapy.7-11 One probable explanation is the time delay involved in instituting intracoronary therapy 16 Regional wall motion was measured along 100 chords constructed perpendicular to a centerline drawn midway between the end-diastolic and end-systolic contours (Figure 1 ), corrected for heart size, and expressed in mean ± SD motion in 52 normal subjects. "Normal subjects" were patients suspected of having heart disease who underwent diagnostic cardiac catheterization but were found to have normal cardiac anatomy, normal coronary arteries, and normal ventricular function. The severity of hypokinesis in the infarct site was calculated hypokinetic half of the infarct artery territory and expressed in SD per chord. Hyperkinesis was similarly calculated in the most hyperkinetic half of the artery territory opposite the infarct site. The derivation of the centerline method has been previously reported. 17 Coronary anatomy was reviewed by an angiographic reading committee blinded to the treatment assignment. The infarct-related vessel was identified as patent or nonpatent, and the residual diameter stenosis of the patent vessels was measured with a digital caliper. Reperfusion was measured as in the Thrombolysis in Myocardial Infarction trial (TIMI): grade 0, no perfusion; grade 1, penetration of the thrombus by contrast with minimal distal perfusion; grade 2, partial perfusion; and grade 3, complete perfusion. The extent of disease in the noninfarct arteries was also assessed. Any diameter stenosis greater than 50% in noninfarct vessels was defined as "significant" for the purposes of determining the presence or absence of multivessel disease.
The t test was used to test for treatment-control differences in continuous variables. The x2 statistic was used for categorical variables.
Results Two hundred fifty (67.9%) of the 368 patients entering the trial underwent follow-up cardiac catheterization for 10.4 ± 7.4 days (range, 1-48 days) after infarction. A comparison of those patients who underwent catheterization with those in whom catheterization was not performed is shown in Table  1 . The group undergoing catheterization was younger and had a higher percentage of men than did the group of survivors who did not undergo catheterization. Figure 2 summarizes the coronary angiographic data. A patent infarct-related artery (TIMI grade 2 or 3 perfusion) was present in 68.5% of treated patients versus 44.8% of controls (p = 0.003). The patency rate was significantly higher for treated than for control patients in the subgroups with anterior and inferior myocardial infarction. Among SK-treated patients, patency rates were higher for anterior (85.4%) than for inferior myocardial infarction (60.7%). The residual diameter stenosis of patent infarct-related arteries was similar for SK-treated patients (65.0 ± 19.0%o) and controls (70.1 ± 17.6%).
Ejection fraction data for all patients and for selected subsets are shown in Figure 3 . Patients treated with SK had a slightly higher ejection fraction (54± 12.1% vs. 51 ± 12.6% for control patients) (p = 0.056). Subset analysis shows that ejection fraction differences were most prominent for those with anterior myocardial infarction and were confined to those patients with a patent infarct-related artery at the time of catheterization.
Regional wall motion analysis revealed that function in the infarct territory was significantly impaired. Mean wall motion was normal or even hypokinetic in SK-treated patients with a nonpatent infarct vessel and in control patients (Figure 4 ). Significant differences were present in subgroups with anterior infarction and in those treated within 3 hours of symptom onset.
Although wall motion in noninfarct regions is greater in treated than control patients with singlevessel disease, significant differences between treated and control patients are confined to those with multivessel disease (Table 2) . This difference is significant regardless of whether patients with a history of a previous myocardial infarction are excluded from the analysis. Discussion Intravenous thrombolytic therapy has been adopted as the most expedient method for achieving reperfusion in the majority of patients with acute myocardial infarction. Several previous myocardial infarction and other baseline clinical parameters were similar in the two groups. In fact, the incidence of pulmonary edema at presentation was higher in SK-treated patients (6%) than in control patients (3%). Although caution is warranted in interpreting post hoc analysis, the subset analysis of ejection fraction is of interest. More striking differences in ejection fraction between SK-treated and control patients were present in patients with anterior myocardial infarction than in those with inferior myocardial infarction. These findings agree with previously published data regarding the effect of intravenous SK on ventricular function. Like in our present study, Bassand et al14 found no treatmentcontrol differences in ejection fraction for inferior myocardial infarction. However, a significant ejection fraction difference favoring SK-treated patients (40% vs. 33%) was reported for the subset with anterior myocardial infarction. White et a13 found a small but statistically significant difference in ejection fraction (60% for SK-treated vs. 55% for control patients) in patients with inferior myocardial infarction and no previous infarction. A larger difference was present for anterior myocardial infarction (57% for SK-treated vs. 49% for control).
Thus, ejection fraction is relatively well preserved, even in control patients with inferior infarction, and is not substantially improved by treatment with SK. This is consistent with the low 1-year mortality previously reported for both treated and untreated patients with inferior myocardial infarction.15 '19 The more substantial effects of SK on ventricular function in patients with anterior myocardial infarction may explain the striking reduction in 1-year mortality among patients with anterior myocardial infarction who are successfully reperfused. 19 There may be several reasons for the lesser benefit in patients with inferior myocardial infarction. Because the right coronary artery supplies a smaller mass of left ventricle than the left anterior descending artery,20 the impact of infarction on global function and maximum amount of salvage possible are less for inferior than for anterior myocardial infarction. A second possible explanation is the lower rate of infarct vessel patency for inferior infarctions at the time of catheterization. Among patients treated with SK in this trial, the left anterior descending artery was patent (TIMI grade 2 or 3) in 85.4% of patients with anterior infarctions, whereas the right coronary artery was patent in only 60.7% of inferior infarctions. A third possible mechanism may relate to the higher incidence of collateral vessels in inferior myocardial infarction as opposed to anterior myocardial infarction observed in this and other studies. 21 In the present study, collaterals were present in 43.2% of inferior myocardial infarctions and 26.7% of anterior myocardial infarctions. Collateral vessels could provide a protective effect in patients failing to reperfuse,22.23 thereby tending to minimize treatment-control differences in ventricular function. However, because we have no data on the prevalence of collaterals in the first few hours of infarction and because collaterals often develop rapidly over the first 2 weeks after myocardial infarction, 24 we cannot be certain of the effect of collaterals in the present study.
The ejection fraction difference between treated and control patients was greatest among those with a patent infarct-related vessel (57% vs. 50%). Presumably, the key difference between these groups was that the vessels in patients receiving SK opened earlier, whereas spontaneous reperfusion in control patients occurs gradually over the initial 24 hours after acute myocardial infarction.25 The importance of early reperfusion in achieving functional recovery has been amply demonstrated. In the TIMI trial, the ejection fraction increased significantly in patients who had a patent infarct artery by 90 minutes after initiation of thrombolytic therapy but not in those whose arteries opened after the 90-minute angiogram and before the predischarge angiogram. 18 Analysis of regional wall motion demonstrates that most patients, regardless of thrombolytic therapy, have severe hypokinesis in the infarct-related territory. The magnitude of the dysfunction measured in the present study is almost identical to that measured by the centerline method in the TIMI trial18 after treatment with either intravenous SK or tissue plasminogen activator. It is interesting to note that the defect in wall motion was similar in severity despite the shorter time to treatment in this trial (3.5 vs. 4.75 hours). In the present study, there was a slight trend toward better regional function for SK-treated patients who were randomized under 3 hours, and in the TIMI trial, recovery was greater in patients reperfused within 4 hours after onset of symptoms. However, both trials had only a few patients who were treated within 2 hours, which is when the potential for salvage appears to be greatest. 26 On average, SK-treated patients displayed mild hyperkinesis in the noninfarct region, whereas control patients did not. Hyperkinesis in areas of the ventricle remote from the site of acute ischemia has been previously noted in human and animal studies. Semiquantitative analysis of two-dimensional echocardiograms performed in the first 24 hours after myocardial infarction has detected remote hyperkinesis in 50-87% of patients.27,28 Using quantitative analysis of contrast ventriculograms obtained within the first 12 hours of infarction, Stadius et a12' documented hyperkinesis in 32% of patients. Hyperkinesis is most prominent in the early hours of infarction and tends to decrease, though not disappear, in the ensuing days and weeks. This response has been attributed to catecholamine activity or regional alterations in preload secondary to left ventricular dilatation with enhanced function of the nonischemic regions due to the Starling mechanism.
Another possible mechanism is reduced regional afterload due to asynchronous contraction of ischemic and nonischemic areas of the ventricle or to decreased tension development, premature relaxation, or frank systolic bulging in the infarcted region.29 Irrespective of the mechanism, the development of compensatory hyperkinesis moderates the impact of acute myocardial infarction on global left ventricular function. Indeed, hyperkinesis may be so great as to normalize the ejection fraction, reducing its sensitivity as a measure of function in the infarct region and of response to therapeutic interventions. 30 Compensatory regional hyperkinesis late after infarction, however, has been less frequently observed. Theroux et a131 related its appearance to the development of hypertrophy in the dog. In the present study, SK-treated patients had significantly more hyperkinesis 1-3 weeks after myocardial infarction than control patients. This difference likely contributed to the overall difference in ventricular function, as measured by the ejection fraction, between SK-treated and control patients. The treatment-control differences in the function of the noninfarct region were greatest in those patients with multivessel disease. Only a small difference was observed between control and treated patients with single-vessel disease. In contrast, SK-treated patients with multivessel disease developed slight hyperkinesis, whereas control patients with multivessel disease had hypokinesis in the contralateral wall as well as the infarct region.
Similar observations regarding the benefit of thrombolytic therapy on the function of noninfarct territories have been made by other investigators.12,14 Serruys et a112 also reported greater function in the noninfarct region in SK-treated patients. Furthermore, hyperkinesis was greatest in patients who had angioplasty after thrombolysis. Their observations were made much later after myocardial infarction than in the present trial, with over one third of patients being studied at a median of 42 12 The contribution of these mechanisms in the present study cannot be determined because the necessary data in only 0-14% of patients with single-vessel disease.
In summary, treatment of acute myocardial infarction with intravenous SK resulted in a higher ejection fraction at the time of hospital discharge. The greatest benefit was seen in patients with anterior myocardial infarction. The improved global function was associated with better function in areas of the ventricle remote from the site of infarction. The small differences in function of the infarct regions did not achieve statistical significance in this trial. These observations indicate that there are multiple mechanisms by which thrombolysis improves ventricular function. The most obvious and most intensively studied mechanism is preservation of mechanical function in the infarct zone by direct salvage of myocardium. However, even when this is not achieved, reperfusion may benefit flow or function in the noninfarct region and thereby also improve global ventricular function, especially in patients with multivessel disease. Further refinement of these observations may lead to a better understanding of the mechanisms by which thrombolytic therapy reduces mortality in acute myocardial infarction.
